AB0391 Sustained Remission and Rate of Relapse after Withdrawal of Biologic or Non-Conventional DMARD in Patients with Rheumatoid Arthritis (RA)

BackgroundRheumatoid arthritis (RA) treatment has changed considerably over the last decade with the introduction of biologics and target synthetic non-conventional DMARDs. In spite of algorithms about when to begin using these drugs, data about when to stop them are scant.ObjectivesTo assess the length of remission in patients with RA who had to discontinue a biological or a non-conventional DMARD because a clinical trial ended, and to compare survival remission curves.MethodsA prospective cohort study of RA patients assembled at the time of their last dose of any of the following drugs: tocilizumab subcutaneous (TCZ-SC), TCZ intravenous (TCZ-IV), or targeted synthetic oral drugs (tsDMARDs) tofacitnib or baricitinib p.o. All patients were in RA remission (DAS-28